Vabysmo (Faricimab) for Retinal Disease

Two large clinical trials, called TENAYA and LUCERNE, compared Vabysmo to a well-established anti-VEGF medication in more than 1,300 patients with wet AMD. Results showed that Vabysmo produced vision improvements comparable to the comparison medication. Nearly 80 percent of patients treated with Vabysmo were able to extend their treatment interval to at least three months after completing the loading phase, and approximately 60 percent extended to four-month intervals.

Two additional trials, YOSEMITE and RHINE, enrolled more than 1,800 patients with DME. Patients treated with Vabysmo gained an average of 11 letters on a standardized eye chart over one year, similar to results achieved with the comparison medication. At the 12-week mark, a higher proportion of patients treated with Vabysmo showed complete resolution of retinal fluid compared to those receiving the comparison treatment, suggesting a stronger drying effect in the retina.

Since Vabysmo became commercially available, more than 60 published real-world studies have examined how it performs in everyday clinical practice. These findings have been consistent with the clinical trial data, confirming that many patients maintain their vision gains while receiving fewer injections per year than they would have needed with older anti-VEGF treatments. This reduction in treatment burden is a meaningful benefit for patients managing long-term retinal conditions.

Eylea (aflibercept) and Lucentis (ranibizumab) are well-established anti-VEGF medications with more than a decade of widespread clinical use and strong long-term safety records. Both target VEGF-A only and typically require injections every four to eight weeks in most patients. Vabysmo's dual-target approach may allow longer intervals between treatments for appropriate candidates. Clinical trials showed vision outcomes with Vabysmo to be comparable to those achieved with Eylea. The right choice between these medications depends on your diagnosis, treatment history, and how your eye responds.

Avastin (bevacizumab) is used off-label for retinal conditions. It was originally FDA-approved for cancer treatment but has been widely studied for retinal use, and large studies have confirmed its effectiveness for many retinal conditions. It is significantly less expensive than newer anti-VEGF agents. However, it typically requires more frequent dosing than Vabysmo. For patients where reducing visit frequency is a priority, Vabysmo's ability to extend intervals may reduce the overall number of annual office visits. Your retina specialist can discuss all available options based on your specific clinical needs and circumstances.

There is no universally best anti-VEGF medication. Each option has its own profile of advantages, and individual responses to treatment vary. Your retina specialist will consider your specific diagnosis, the severity and activity of your condition, your prior treatment history, and your personal preferences when recommending a plan. Switching between medications is a common and accepted part of managing retinal disease, and your specialist will adjust your treatment if the initial approach does not achieve the desired result.

After completing the four-injection loading phase, your schedule will be adjusted based specifically on how your eye responds. Many patients extend to every two or three months, and some reach four-month intervals. However, not everyone achieves the longest possible intervals, and that does not mean the treatment is not working. The goal is always to find the longest interval at which your retina stays dry and your vision remains stable. Your specialist reassesses this at every visit, so the schedule continues to reflect your eye's current status rather than a fixed plan.

The eye is thoroughly numbed before each injection, and the vast majority of patients describe the experience as brief pressure rather than sharp pain. Some patients notice mild soreness or a scratchy feeling for a day or two afterward, which is a normal response to the injection. If you experience increasing pain rather than mild, improving discomfort in the days following an injection, that is a reason to contact our office promptly rather than waiting for your next scheduled visit.

The most relevant practical difference for patients is the possibility of longer intervals between treatments. Because Vabysmo stabilizes retinal blood vessels through two pathways instead of one, the effects may last longer for many patients. For someone managing a long-term condition that requires ongoing treatment, this can translate to a meaningfully smaller number of office visits each year. Whether you personally are able to extend intervals depends on how your eye responds, which your specialist evaluates carefully at every appointment.

Vision improvement is possible and tends to be most significant when treatment begins before severe or prolonged retinal damage has occurred. Results vary considerably from person to person. Some patients gain meaningful lines of vision on a standardized eye chart, while others experience stabilization that prevents further loss. Vision that has been lost due to advanced retinal scarring or long-standing damage may not be fully recoverable. That said, halting further vision loss is itself an important and worthwhile treatment goal, and it is one that Vabysmo is designed to help achieve.

For conditions like wet AMD, long-term ongoing treatment is typically necessary to maintain vision. Your specialist will monitor your condition over time and adjust your plan as needed. For DME, treatment may eventually be paused in some patients once the condition has fully stabilized, but this is not a guaranteed outcome and requires careful monitoring before any change is made. Regardless of how well your condition is controlled, regular follow-up appointments remain essential to detect any early signs of change before vision is affected.

Contact our office as soon as you know you need to reschedule. Missing or significantly delaying injections can allow retinal fluid to return and may lead to vision loss, particularly in conditions like wet AMD that can progress quickly. Our team will work to get you rescheduled as promptly as possible. If you notice new or worsening visual symptoms before your rescheduled visit, do not wait. Reach out to us right away so we can determine whether you need to be seen sooner.